Biogaia Ab Class B · OMXSTO:BIOG_B
Biogaia Ab Class B — Q4 2025 Earnings Presentation
20 slides from Biogaia Ab Class B's earnings presentation, Feb 12, 2026
Slide 1: Q4 2025 Results Telephone Conference
Q4 2025 RESULTS Telephone Conference 12 February 2026 Theresa Agnew, CEO Alexander Kotsinas, CFO
Slide 2: Financial highlights Q4 2025
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Financial highlights Q4 2025 ORGANIC EBIT FREE GROWTH MARGIN CASHFLOW 32% 27% 77MSEK 2
Slide 3: Executive Summary Q4 2025
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Executive Summary Q4 2025 • Net sales for the year reached 1,538 MSEK, an increase of 14% in organic growth compared with 2024 (+8% adjusted for currency effects) • In the
Slide 4: BioGaia Strategy
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks BioGaia Strategy Expansion through Grow Direct Markets the Core Gut Health / Colic Oral Health Immune Health Breakthrough Innovation Foundations People & Culture Invest for
Slide 5: Delivering on Our Strategy
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Delivering on Our Strategy • Driving growth of Pediatric and Adult segments • Investing in marketing and sales activities to drive strong growth in direct markets Grow the
Slide 6: Launches
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Launches Distributor Country Product Abbott Oman BioGaia Protectis drops Abbott Qatar BioGaia Protectis drops Abbott Bahrain BioGaia Protectis drops Ewopharma Lithuania Bio
Slide 7: Key Events
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Key Events • October 16: BioGaia announced that the study on BioGaia’s new patented strain L. reuteri BG-R46® has been published in Beneficial Microbes • October 28: BioGai
Slide 8: Organic Growth by Business Segment Q4
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Organic Growth by Business Segment Q4 Total Pediatrics Adults +32% +34% +27% 75% share of revenue 24% share of revenue Sales increased mainly due to increased sales of Prot
Slide 9: Sales per Segment
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Sales per Segment Sales per Segment Q4 2025 Q4 Q4 Organic Total YTD YTD Organic Total 1% MSEK 2025 2024 change change 2025 2024 change change 24% Pediatrics 332 270 34% 23%
Slide 10: Sales per Region
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Sales per Region Sales per Region Q4 2025 Organic Organic Q4 Q4 YTD YTD MSEK change Change change Change 2025 2024 2025 2024 35% 33% EMEA 147 114 34% 28% 497 507 1% -2% APA
Slide 11: Financials
Alexander Kotsinas, CFO Financials 11
Slide 12: Key Financials
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Key Financials Sales (MSEK) Gross profit (MSEK) EBIT (MSEK) +21% +25% 441 324 365 259 +17% 121 103 71% 74% 28% 27% Q4 2024 Q4 2025 Q4 2024 Q4 2025 Q4 2024 Q4 2025 12
Slide 13: Sales Bridge
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Sales Bridge +21% 116 -40 441 365 Q4 2024 Organic Currency Q4 2025 growth effect Change 32% -11% 13
Slide 14: Gross Margin per Segment
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Gross Margin per Segment Gross margin Q4 2025 Q4 2024 YTD 2025 YTD 2024 Pediatrics 76% 72% 76% 75% Adult Health 64% 67% 66% 63% Total 74% 71% 73% 72% • Pediatrics: Gross ma
Slide 15: Operating Expenses (OPEX)
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Operating Expenses (OPEX) MSEK Q4 2025 Q4 2024 Change YTD 2025 YTD 2024 Change Sales and Marketing -146 -121 21% -513 -423 21% Research and Development -37 -34 9% -116 -157
Slide 16: Profit and Loss Statement
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Profit and Loss Statement MSEK Q4 2025 Q4 2024 Change YTD 2025 YTD 2024 Change Sales 441 365 21% 1,538 1,423 8% Gross profit 324 259 25% 1,129 1,031 9% Percentage of revenu
Slide 17: Cashflow
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Cashflow MSEK Q4 2025 Q4 2024 Change YTD 2025 YTD 2024 Change Cash flow from operating activities before 109 94 +14 349 423 -74 changes in net working capital Changes in wo
Slide 18: Concluding Remarks
Executive summary Sales breakdown Financials Concluding remarks Executive summary Sales breakdown Financials Concluding remarks Concluding Remarks Q4 2025 • The fourth quarter shows organic sales increase of 32% (21% including foreign exchange effects). Order variability in the fourth quarter was ap
Slide 19: Q&A
Q&A
Slide 20: BioGaia.
BioGaia.